Spero Therapeutics (SPRO) Proxy Filing summary

Executive summary

• Annual meeting scheduled for June 12, 2025, to be held virtually for shareholder participation.

• Shareholders can access proxy materials online or request paper/email copies before May 29, 2025.

Voting matters and shareholder proposals

• Election of three Class II directors to serve until the 2028 annual meeting or until successors are qualified.

• Ratification of PricewaterhouseCoopers LLP as independent auditor for fiscal year ending December 31, 2025.

• Advisory vote to approve named executive officer compensation as disclosed in the proxy statement.

• Approval of amendment to the 2017 Stock Incentive Plan to increase authorized shares by 3,000,000.

• Provision to transact other business properly presented at the meeting or any adjournments.

Board of directors and corporate governance

• Nominees for Class II director positions: Frank E. Thomas, Patrick Vink, M.D., and Esther Rajavelu.